As part of its continued expansion of services in Latin America, Marken has announced the planned September 1, 2011 launch of their Latin America regional depot network with facilities in Mexico City and Buenos Aires.
Marken is executing on its stated plan to build the most advanced, fit for purpose, pharmaceutical-focused clinical distribution network. This expanded network allows the company to build from its current industry-leading life sciences logistics platform, which serves over 6,000 investigator sites in 100 countries from its 24 global branch offices.
The Singapore facility is fully operational and has been successfully audited by several client companies. Additional depot facilities are planned in the Middle East, Europe, Asia and the Americas. This global network of direct-controlled, GMP-compliant depots allows maximum efficiency in the conduct of clinical trials, even in clinically-naïve regions.
“The expansion of these facilities is just one more step in supporting our clients’ needs in controlling the chain-of-custody of clinical trial assets.” said Wes Wheeler, Marken’s Chief Executive Officer. “Our goal is to be the premier provider of life sciences supply chain services. We are 100% focused on life sciences and will ensure that the strict requirements unique to the pharmaceutical and medical device communities are met, particularly with the recent focus on new regulatory documentation, strict temperature control and chain of custody.”
Each of Marken’s depots will also offer specimen kit distribution, collection, storage and management; and reverse logistics for dosage kits, drugs and equipment, including reconciliation and certified destruction. The Mexico and Argentina storage facilities include the full range of temperature control including controlled ambient, cold storage (2º-8ºC) and frozen (-20ºC) as well as secured drug store.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.